Pharminent

Kite details filing plans for lead CAR-T

If all goes according to plan, Kite’s KTE-C19 could be the first CAR-T approved in the U.S. http://www.biopharmadive.com/news/kite-cart-kte-c19-filing-fda/430147/

Filed under: Cancer, Immunotherapy